IJLH:使用西门子ADVIA 2120i和“APL标准”可以帮助降低APL的早期死亡率

2019-06-02 不详 网络

急性早幼粒细胞白血病(APL)是一种急性髓系白血病(AML),具有危及生命的凝血障碍。一旦疑似APL,就应该启动ATRA。因此,了解APL的细节是至关重要的,但有些情况下可能缺乏经验丰富的血液病理学家。因此,我们开发了一种基于自动血细胞计数器ADVIA 2120i Siemens生成的参数来辅助APL诊断的算法。 根据APL的病理生理学特点和分析仪的技术特点,选择了算法中的所有参数。采用c1

急性早幼粒细胞白血病(APL)是一种急性髓系白血病(AML),具有危及生命的凝血障碍。一旦疑似APL,就应该启动ATRA。因此,了解APL的细节是至关重要的,但有些情况下可能缺乏经验丰富的血液病理学家。因此,我们开发了一种基于自动血细胞计数器ADVIA 2120i Siemens生成的参数来辅助APL诊断的算法。

根据APL的病理生理学特点和分析仪的技术特点,选择了算法中的所有参数。采用c1截止:PLT < 150×103;% Mono < 10;% LUC < 4;%嗜铬细胞> 2;%饱和细胞≥1;% blasts > 4。在满足至少5 / 6的截断条件下,我们得到了一个“APL准则”。测试了247.209例来自常规和紧急样本的原始数据,124例来自APL的原始数据。我们进行了多参数分析,并获得了确定的截止点(c2)。它通过常规和紧急情况下的一组51.002原始数据进行了验证。最后,对AMLALLMDSMPN、肿瘤样本以及溶血性和巨幼细胞性贫血进行了检测。

该算法对白细胞数高或正常的APL具有较高的敏感性(86.30%)和特异性(99.83%),对白细胞减少的APL具有较好的结果(80%)。这种特异性在血液学和非血液学疾病中也非常高。它可以作为一个“APL标准”来提醒病理学家可能存在APL

研究表明,该方法与仪器形态学和经典形态学相结合,可以缩短诊断时间,进一步减少早期死亡。

原始出处:

Vincenzo Rocco, Christian Castelli ,The diagnostic use of ADVIA 2120i Siemens and an APL criteria can help to reduce the rate of early death in the APL

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1973255, encodeId=5f1f19e325519, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 28 16:25:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779991, encodeId=17521e799916b, content=<a href='/topic/show?id=f3f226484d' target=_blank style='color:#2F92EE;'>#APL标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2648, encryptionId=f3f226484d, topicName=APL标准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Feb 04 11:25:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666913, encodeId=77e1166691396, content=<a href='/topic/show?id=f2b0905506a' target=_blank style='color:#2F92EE;'>#西门子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90550, encryptionId=f2b0905506a, topicName=西门子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e226073684, createdName=bshuang, createdTime=Fri Mar 27 17:25:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509526, encodeId=e59c15095265c, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Tue Jun 04 09:25:00 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1973255, encodeId=5f1f19e325519, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 28 16:25:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779991, encodeId=17521e799916b, content=<a href='/topic/show?id=f3f226484d' target=_blank style='color:#2F92EE;'>#APL标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2648, encryptionId=f3f226484d, topicName=APL标准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Feb 04 11:25:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666913, encodeId=77e1166691396, content=<a href='/topic/show?id=f2b0905506a' target=_blank style='color:#2F92EE;'>#西门子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90550, encryptionId=f2b0905506a, topicName=西门子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e226073684, createdName=bshuang, createdTime=Fri Mar 27 17:25:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509526, encodeId=e59c15095265c, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Tue Jun 04 09:25:00 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1973255, encodeId=5f1f19e325519, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 28 16:25:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779991, encodeId=17521e799916b, content=<a href='/topic/show?id=f3f226484d' target=_blank style='color:#2F92EE;'>#APL标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2648, encryptionId=f3f226484d, topicName=APL标准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Feb 04 11:25:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666913, encodeId=77e1166691396, content=<a href='/topic/show?id=f2b0905506a' target=_blank style='color:#2F92EE;'>#西门子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90550, encryptionId=f2b0905506a, topicName=西门子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e226073684, createdName=bshuang, createdTime=Fri Mar 27 17:25:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509526, encodeId=e59c15095265c, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Tue Jun 04 09:25:00 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
    2020-03-27 bshuang
  4. [GetPortalCommentsPageByObjectIdResponse(id=1973255, encodeId=5f1f19e325519, content=<a href='/topic/show?id=7cc35939955' target=_blank style='color:#2F92EE;'>#早期死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59399, encryptionId=7cc35939955, topicName=早期死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Dec 28 16:25:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779991, encodeId=17521e799916b, content=<a href='/topic/show?id=f3f226484d' target=_blank style='color:#2F92EE;'>#APL标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2648, encryptionId=f3f226484d, topicName=APL标准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Feb 04 11:25:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666913, encodeId=77e1166691396, content=<a href='/topic/show?id=f2b0905506a' target=_blank style='color:#2F92EE;'>#西门子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90550, encryptionId=f2b0905506a, topicName=西门子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3e226073684, createdName=bshuang, createdTime=Fri Mar 27 17:25:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509526, encodeId=e59c15095265c, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Tue Jun 04 09:25:00 CST 2019, time=2019-06-04, status=1, ipAttribution=)]
    2019-06-04 风铃824

相关资讯

急性早幼粒细胞白血病治愈率高达90%!国人新发现再获国际大奖!

2018年2月5日晚,2018年度舍贝里将公布。获奖者为:陈竺教授、安娜.德让(Anne Dejean)、修格.德.特(Hugues De The)。其中陈竺教授为上海交通大学医学院瑞金医院终身教授。

儿童急性早幼粒细胞白血病诊疗规范(2018年版)

为落实国家卫生健康委、国家发展改革委、人力资源社会保障部、国家医保局、国家中医药局、国家药监局联合印发的《关于开展儿童白血病救治管理工作的通知》要求,进一步提高儿童白血病诊疗规范化水平,保障医疗质量与安全,组织制定了儿童急性早幼粒细胞白血病诊疗规范(2018年版)。

2019 ELN专家建议:急性早幼粒细胞白血病的管理(更新)

2019年2月,欧洲白血病网(ELN)更新发布了急性早幼粒细胞白血病的管理建议,该建议是对2009年版建议的更新,主要建议内容涉及急性早幼粒细胞白血病的诊断检查和支持性治疗,诱导、维持以及巩固治疗,特殊情况的管理,疾病复发的管理。

Blood:减少蒽环霉素、增加全反式维甲酸剂量,不影响急性早幼粒细胞白血病患儿预后

中心点:用风险适应性疗法治疗儿童APL可获得很高的治愈率。减少蒽环霉素的累积剂量、延长ATRA应用时间,不影响APL患儿预后。摘要:小儿急性早幼粒细胞白血病(APL)是一种罕见的儿童肿瘤,可通过全反式维甲酸(ATRA)和蒽环霉素治愈。但是,迄今为止,大多已发表的临床试验都是使用了高累积剂量的蒽环霉素。Anna Maria Testi等人开展一国际性临床试验(ICC-APL-01),评估减少蒽环霉素

Lancet oncol:口服砒霜+全反式维甲酸或可代替标准三氧化二砷+全反式维甲酸治疗非高风险急性早幼粒细胞白血病!

静脉注射三氧化二砷联合全反式维甲酸(ATRA)(无化疗)是非高风险急性早幼粒细胞白血病(白细胞计数≤10x109/L)的标准疗法,可治愈95%以上的病例。但是,一试验性研究,采用口服砒霜(RIF)联合ATRA(无化疗)治疗,比标准静脉疗法更方便,疗效显着。现研究人员对RIF+ATRA与标准静脉三氧化二砷+ATRA疗法治疗非高风险急性早幼粒白血病的效果进行对比。研究人员在中国14个中心进行一非劣效性

Leukemia:儿童急性早幼粒细胞白血病开展精准诊治研究进展

国家儿童医学中心、上海交通大学医学院附属上海儿童医学中心血液肿瘤科李本尚教授、汤静燕教授团队近日在血液学权威学术杂志《Leukemia》发表了关于儿童急性早幼粒细胞白血病(APL)精准诊治方面的研究成果(The genetics and clinical characteristics of children morphologically diagnosed as acute promyeloc